Your browser doesn't support javascript.
loading
Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma.
Spiliopoulou, Pavlina; Spear, Sarah; Mirza, Hasan; Garner, Ian; McGarry, Lynn; Grundland-Freile, Fabio; Cheng, Zhao; Ennis, Darren P; Iyer, Nayana; McNamara, Sophie; Natoli, Marina; Mason, Susan; Blyth, Karen; Adams, Peter D; Roxburgh, Patricia; Fuchter, Matthew J; Brown, Bob; McNeish, Iain A.
Afiliación
  • Spiliopoulou P; Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom.
  • Spear S; Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Mirza H; Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom.
  • Garner I; Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom.
  • McGarry L; Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom.
  • Grundland-Freile F; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
  • Cheng Z; Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom.
  • Ennis DP; Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom.
  • Iyer N; Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom.
  • McNamara S; Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Natoli M; Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom.
  • Mason S; Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom.
  • Blyth K; Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom.
  • Adams PD; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
  • Roxburgh P; Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Fuchter MJ; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
  • Brown B; Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • McNeish IA; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
Mol Cancer Ther ; 21(4): 522-534, 2022 04 01.
Article en En | MEDLINE | ID: mdl-35131874
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Cistadenocarcinoma Seroso Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Cistadenocarcinoma Seroso Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos